minocycline

Microglia inhibition or depletion by treating organotypic cultures with minocycline or PLX3397 resulted in reduced levels of all the evaluated cytokines in the medium, confirming the role of microglia in the inflammatory microenvironment of glioblastoma. These findings provide valuable insights into how microglia interact with tumors and healthy cells in the tumor microenvironment, driving neuroinflammation and tumor cell dedifferentiation. This understanding could pave the way for the development of innovative therapies for glioblastoma.

We demonstrated that pioglitazone and minocycline protected against glutamate-induced axonal injury, rotenone-induced neuronal death and promoted oligodendrocyte differentiation. In summary, our findings demonstrate that human preclinical IPSC platforms can be used to characterize the neuroprotective properties of compounds and thus may aid the selection of drugs for clinical trials. Moreover, the platform's flexibility allows for the easy incorporation of additional disease-specific phenotypic assays.

To investigate the suppressive action of TX on M1 polarization, BV2 cells were stimulated with LPS and then treated with TX or minocycline (MINO)...TX suppresses pro-inflammatory induction after LPS stimulation of BV2 microglia, which may be related to the NF-κB inhibition and accelerated HO-1/Nrf2 activation. These findings pinpoint the potential therapeutic potential of TX in inflammation-induced neurodegenerative diseases.

P=N/A, N=147, Not yet recruiting, The Zhongshan Ophthalmic Center,Sun Yat-sen University; The Zhongshan Ophthalmic Center,Sun Yat-sen University

P=N/A, N=316, Not yet recruiting, Sir Run Run Hospital, Nanjing Medical University; Sir Run Run Hospital, Nanjing Medical University

P2, N=34, Completed, University of Florida | Recruiting --> Completed | Phase classification: P4 --> P2

An uncomplicated, widely available, prophylactic regimen (COCOON DM) reduced the incidence of DAEIs with amivantamab-lazertinib and the impact of symptoms on QoL.

P1/2, N=33, Recruiting, TenNor Therapeutics Inc. | N=23 --> 33

P2, N=300, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2026 --> Jan 2032 | Trial primary completion date: Nov 2025 --> May 2027

However, local injection of the microglia inhibitor minocycline into the mPFC markedly alleviated pain-induced anxiety-like behaviors...These results suggest that aberrant phagocytosis of excitatory synapses by microglia in the mPFC participates in regulating pain-induced anxiety-like behaviors, likely through MERTK. Pharmacological and non-pharmacological approaches (e.g., EA) targeting microglial phagocytosis in the mPFC may represent novel therapeutic strategies for chronic pain comorbid with anxiety and depression.

He was diagnosed with periocular dermatitis initially, but when his condition failed to improve with minocycline, he was subsequently diagnosed with papulopustular rosacea and impetigo...This case report highlights the importance of integrating both clinical presentation and histopathologic findings to establish a diagnosis of LyP, especially when it arises in an uncommon anatomic site. LyP typically follows a benign course, but all patients diagnosed with LyP should have regular visits with a hematologist/oncologist to monitor for potential progression to malignant lymphoma.

Drug-gene interaction analysis identified Marimastat, Bosentan, and Minocycline as potential therapeutic agents that target key molecular pathways shared across COPD, LUAD and LUSC. This study represents the initial effort to map TF-miRNA-DEG-drug networks across COPD and both the LUAD and LUSC subtypes. These results suggest potential biomarkers for early diagnosis and highlight opportunities for drug repurposing to mitigate COPD-associated lung cancer risk.